# DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

> **NCT07070440** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** DZD6008
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07070440
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07070440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07070440, "DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07070440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*